QR-koda

Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis

Aim of the study Lebrikizumab monotherapy demonstrated efficacy for adults and adolescents with moderate-to-severe atopic dermatitis (AD). This study aims to evaluate the relationship between lebrikizumab serum levels and stable deep response after treatment cessation in Week 16-responder patients w...

Olles dieđut

Furkejuvvon:
Váldodahkkit: Jonathan I. Silverberg, Thomas Bieber, Kilian Eyerich, April W. Armstrong, Brian J. Nickoloff, Chitra R. Natalie, Gaia Gallo, Angela Okragly, Eric Wolf, Chenjia Xu, Brian A. Moser, Maria Jose Rueda, Hany Elmaraghy, Ozge Uluckan, Johann E. Gudjonsson
Materiálatiipa: Artigo
Giella:Inglês
Almmustuhtton: Taylor & Francis Group 2026-12-01
Ráidu:Journal of Dermatological Treatment
Fáttát:
Lebrikizumab
EASI 90
remission
atopic dermatitis
Liŋkkat:https://www.tandfonline.com/doi/10.1080/09546634.2026.2636417
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid